181 related articles for article (PubMed ID: 27560107)
1. The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms.
Holmström MO; Riley CH; Svane IM; Hasselbalch HC; Andersen MH
Leukemia; 2016 Dec; 30(12):2413-2416. PubMed ID: 27560107
[No Abstract] [Full Text] [Related]
2. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Imai M; Araki M; Komatsu N
Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms.
Cimen Bozkus C; Roudko V; Finnigan JP; Mascarenhas J; Hoffman R; Iancu-Rubin C; Bhardwaj N
Cancer Discov; 2019 Sep; 9(9):1192-1207. PubMed ID: 31266769
[TBL] [Abstract][Full Text] [Related]
5. A novel molecular assay using hybridisation probes and melt curve analysis for
Keaney T; O'Connor L; Krawczyk J; Abdelrahman MA; Hayat AH; Murray M; O'Dwyer M; Percy M; Langabeer S; Haslam K; Glynn B; Mullen C; Keady E; Lahiff S; Smith TJ
J Clin Pathol; 2017 Aug; 70(8):662-668. PubMed ID: 28143941
[TBL] [Abstract][Full Text] [Related]
6. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
7. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
8. [New disease markers within the chronic myeloproliferative neoplasms].
Holmström MO; Ocias LF; Kallenbach K; Kjær L; Kristensen TK; Pallisgaard N; Petersen BL; Skov V; de Stricker K; Larsen TS; Hasselbalch HC
Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967091
[TBL] [Abstract][Full Text] [Related]
9. CALR mutation studies in chronic neutrophilic leukemia.
Lasho TL; Elliott MA; Pardanani A; Tefferi A
Am J Hematol; 2014 Apr; 89(4):450. PubMed ID: 24421250
[No Abstract] [Full Text] [Related]
10. Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.
Andrici J; Farzin M; Clarkson A; Sioson L; Sheen A; Watson N; Toon CW; Koleth M; Stevenson W; Gill AJ
Pathology; 2016 Jun; 48(4):319-24. PubMed ID: 27114372
[TBL] [Abstract][Full Text] [Related]
11. CALR mutation profile in Irish patients with myeloproliferative neoplasms.
Haslam K; Conneally E; Flynn CM; Cahill MR; Gilligan O; O'Shea D; Langabeer SE
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):112-5. PubMed ID: 27352261
[TBL] [Abstract][Full Text] [Related]
12. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED
Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170
[TBL] [Abstract][Full Text] [Related]
13. Lack of myeloproliferative neoplasm-associated CALR mutations in acute promyelocytic leukemia.
Langabeer SE; Haslam K
Leuk Lymphoma; 2015 Apr; 56(4):1168-9. PubMed ID: 25115510
[No Abstract] [Full Text] [Related]
14. CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum.
Guglielmelli P; Nangalia J; Green AR; Vannucchi AM
Am J Hematol; 2014 May; 89(5):453-6. PubMed ID: 24458922
[No Abstract] [Full Text] [Related]
15. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms.
Jones AV; Ward D; Lyon M; Leung W; Callaway A; Chase A; Dent CL; White HE; Drexler HG; Nangalia J; Mattocks C; Cross NC
Leuk Res; 2015 Jan; 39(1):82-7. PubMed ID: 25499808
[TBL] [Abstract][Full Text] [Related]
16. No detection of atypical one-base deletion of CALR exon 9 with fragment analysis: A molecular trap to avoid.
Lemoine S; Renard M; Bouvier A; Orvain C; Giltat A; Cottin L; Blanchet O; Hunault-Berger M; Ugo V; Luque Paz D
Blood Cells Mol Dis; 2021 Sep; 90():102589. PubMed ID: 34214802
[No Abstract] [Full Text] [Related]
17. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
18. A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients.
Xu N; Ding L; Yin C; Zhou X; Li L; Li Y; Lu Q; Liu XL
Ann Hematol; 2015 May; 94(5):865-7. PubMed ID: 25366168
[No Abstract] [Full Text] [Related]
19. Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling.
Eder-Azanza L; Navarro D; Aranaz P; Novo FJ; Cross NC; Vizmanos JL
Leukemia; 2014 Oct; 28(10):2106-9. PubMed ID: 24919806
[No Abstract] [Full Text] [Related]
20. Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.
Kjær L; Cordua S; Holmström MO; Thomassen M; Kruse TA; Pallisgaard N; Larsen TS; de Stricker K; Skov V; Hasselbalch HC
PLoS One; 2016; 11(10):e0165336. PubMed ID: 27764253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
